|Home | About | Journals | Submit | Contact Us | Français|
Improved diagnostics for typhoid are needed; a typhoid controlled human infection model may accelerate their development and translation. Here, we evaluated a blood culture-PCR assay for detecting infection after controlled human infection with S. Typhi and compared test performance with optimally performed blood cultures.
Culture-PCR amplification of blood samples was performed alongside daily blood culture in 41 participants undergoing typhoid challenge. Study endpoints for typhoid diagnosis (TD) were fever and/or bacteraemia. Overall, 24/41 (59%) participants reached TD, of whom 21/24 (86%) had ≥1 positive blood culture (53/674, 7.9% of all cultures) or 18/24 (75%) had ≥1 positive culture-PCR assay result (57/684, 8.3%). A further five non-bacteraemic participants produced culture-PCR amplicons indicating infection; overall sensitivity/specificity of the assay compared to the study endpoints were 70%/65%. We found no significant difference between blood culture and culture-PCR methods in ability to identify cases (12 mismatching pairs, p = 0.77, binomial test). Clinical and stool culture metadata demonstrated that additional culture-PCR amplification positive individuals likely represented true cases missed by blood culture, suggesting the overall attack rate may be 30/41 (73%) rather than 24/41 (59%). Several participants had positive culture-PCR results soon after ingesting challenge providing new evidence for occurrence of an early primary bacteraemia.
Overall the culture-PCR assay performed well, identifying extra typhoid cases compared with routine blood culture alone. Despite limitations to widespread field-use, the benefits of increased diagnostic yield, reduced blood volume and faster turn-around-time, suggest that this assay could enhance laboratory typhoid diagnostics in research applications and high-incidence settings.
The culture-PCR assay for detection of fliC-D DNA in human blood samples.
Typhoid fever, a non-specific febrile illness caused by infection with Salmonella enterica serovar Typhi (S. Typhi), is common in tropical regions.1 A key limitation to improving the control of typhoid fever is the lack of reliable diagnostic tests.2, 3 In addition to confirming infection in individuals, accurate laboratory diagnostics are needed to ascertain true disease burden, to improve understanding of the natural history of infection in humans, and to evaluate vaccine efficacy.1, 2, 4
Diagnostic approaches for typhoid infection are broadly aimed either at directly detecting bacteria or bacterial products or measuring the host response in clinical samples.2, 4, 5 Blood culture remains the diagnostic technique of choice, but only identifies 45–70% of confirmed cases, even with the availability of newer continuous automated culture systems.5, 6, 7 Serological tests including the Widal test are widely available in endemic settings, although in the absence of paired clinical samples or background population serosurveillance data these tests perform poorly with low sensitivity and specificity.5, 8
Given the poor accuracy of currently available diagnostic tests, attempts have been made to develop PCR-based assays to detect bacterial DNA.9, 10, 11, 12, 13 Few, if any, of these approaches have been instituted in clinical settings mainly due to the difficulty of validating tests when using ‘real-life’ specimens, in which only few, mostly intracellular bacteria (median, 0.5 CFU/mL blood) are present.2, 14 One method to increase the sensitivity of S. Typhi detection from blood is to use ox-bile as a selective culture media.15, 16 Ox-bile reduces both coagulation and serum complement killing activity and causes the selective lysis of human rather than Salmonella cells.17, 18 Recently, we developed a culture-PCR assay incorporating a brief pre-incubation in ox-bile along with PCR amplification of the S. Typhi flagellin gene, fliC.19, 20 Here, we have evaluated this culture-PCR assay as a diagnostic for detecting S. Typhi in the blood of healthy adult volunteers developing typhoid while participating in a human challenge model.21
Challenge of healthy adults with a single oral dose of a wild-type S. Typhi Quailes strain was performed in a dose-escalation study, as previously described.4, 21 Briefly, healthy consenting adult volunteers aged between 18 and 60 years were challenged by ingesting a fresh preparation of 103 or 104 CFU of S. Typhi suspended in sodium bicarbonate solution. After challenge, participants were reviewed daily for symptoms and signs of typhoid fever and clinical samples were collected (Table 1). If the study endpoint of typhoid diagnosis (TD) was reached, additional samples were collected and antimicrobial treatment was initiated. All remaining participants were given antimicrobial treatment on day 14. TD criteria were clinical (temperature ≥38 °C sustained for 12 h) and/or microbiological (positive blood culture).
Blood for culture was collected daily for 14 days or up to 96 h after TD, whichever was the later, and processed according to national standard methods as previously described.21, 22 At all time points after challenge 10 mL blood was collected, except at TD when this was reduced to 5 mL (Table 1). Stool culture was performed as previously described.21 Bacterial isolates were identified by phenotypic, biochemical and serological testing according the Kauffmann-White classification, following standard methods.23, 24
To perform the culture-PCR assay, 5 mL of heparinised peripheral venous blood was collected at daily after challenge (Table 1), and performed as previously described.19, 20, 25 Briefly, blood was added to culture media (20 mL 3% (w/v) ox bile/tryptone soya broth containing 1.5 μL micrococcal nuclease) and incubated for 5 h (37 °C, 220 rpm New Brunswick, Excella e24). Bacteria were then concentrated by centrifugation at 6000 ×g for 20 min and the supernatant removed. DNA was extracted from the bacterial pellet using UltraClean™ BloodSpin™ kits following the manufacturer's instructions, except that elution of the final DNA was performed using 50 μL of pre-heated ‘Buffer 5’ (65 °C for 5 min) prior to centrifugation. PCR amplification was performed with primers targeting the S. Typhi flagellin gene, fliC-d (GenBank L21912,26) as described by Levy et al.10
Amplification reactions were performed in 50 μL volumes containing 10 μL DNA template and 0.2 μM each of H-for and Hd-rev primers (TopTaq PCR Master Mix Kit, Qiagen). Where required, distilled H2O and/or non-study DNA extracted from healthy donor blood was used as negative controls; genomic DNA extracted from S. Typhi Quailes strain culture was used as a positive control template. DNA amplification was performed using standard thermocycler equipment at: 95 °C for 5 min followed by 35 cycles of 93 °C for 30 s, 55 °C/30 s, and 72 °C/40 s and terminating with 1 cycle of 72 °C for 5 min. The specific target PCR amplicons could be observed at 763 bp when separated by 1% (w/v) ethidium bromide agarose gel electrophoresis and visualized using UV light transillumination. Amplicons were categorised as either being present (positive) or absent (negative) by visualisation with the naked eye.
Prior to the investigation of clinical specimens, assay performance and laboratory sensitivity was evaluated using S. Typhi -negative whole blood (5 mL) containing known concentrations of S. Typhi DNA, added after the incubation step (Supplementary Fig. 1). The calculated sensitivity of PCR amplification was at least 0.015 ρg/μL, equivalent to a DNA starting concentration of 30 bacteria per reaction (each bacterium containing ~5 fg DNA)27, 28 or ≥6 CFU/mL in the original starting blood volume, assuming no multiplication had taken place during incubation.
Data pertaining to the diagnostic accuracy of the PCR assay in comparison with the predefined study endpoint of typhoid diagnosis (TD) or positive blood culture are reported according to the STARD criteria.29 The diagnostic accuracy of PCR or blood culture in comparison to TD are reported using sensitivity, specificity, positive and negative likelihood ratios, positive and negative predictive values and diagnostic odds ratio, each with a 95% confidence interval. The statistical significance of the differences in sensitivities of PCR and blood culture was assessed by discordant pairs analysis using a two-tailed binomial test. Data were analysed using Prism v6.0e (GraphPad Software Inc).
The challenge study was approved by the National Research Ethics Service (Oxfordshire Research Ethics Committee A, 10/H/0604/53) and was performed in accordance with the principles of the ICH-Good Clinical Practice guidelines and amendments. All study participants provided written informed consent in accordance with the Declaration of Helsinki. While all blood culture and PCR data were generated prospectively during the study, only blood culture results were used to make clinical management decisions.
Using a dose-escalation approach to determine the optimal challenge dose, 41 participants were challenged with either 103 or 104 CFU of S. Typhi Quailes strain, as previously described.21 Attack rates were 55% and 65% for each dose, respectively; the median day of illness onset was seven days after challenge.
Overall, 684 serial samples were collected for culture-PCR from 41 challenge participants, 24 of whom were diagnosed with typhoid fever (TD). One individual was treated before day 14 based on symptoms alone without fulfilling the study TD criteria (included here in the nTD group, Supplementary Table 1); the remaining 16 participants were treated with antimicrobials at day 14 but did not develop infection, defined as not diagnosed with typhoid (nTD, Table 2). From the 684 samples collected 57 (8.3%) were positive by culture-PCR assay, and were collected from 23 study participants (Fig. 1). From three days after challenge onwards, nTD and TD participants yielded 11/203 (5.4%) and 37/332 (11.1%) positive culture-PCR assay results, respectively. After the initiation of antimicrobials 6/24 (25%) TD participants generated nine further positive culture-PCR assay results, of which 5/9 occurred within six hours of initiated antimicrobial treatment (e.g. Fig. 2).
In comparison with the culture-PCR methods, blood culture alone yielded 53/674 (7.9%) positive samples from the 41 study participants. Positive PCR amplifications were evident earlier in the challenge course than with culture, however the maximal day of blood culture and PCR positivity was six days after challenge for both assays (Fig. 3).
The earliest positive culture-PCR sample was collected only six hours after challenge; a further two participants were positive by 12 h. In total, nine positive samples from seven participants were obtained ≤48 h after the ingestion of S. Typhi with blood samples from a further two participants testing positive within 72 h (Table 2 and Fig. 3). There was no significant association between early stool shedding and culture-PCR assay positivity (n = 3/16, p = 0.63, Fisher's exact test; Fig. 2). Similarly, an early positive culture-PCR result was not predictive of subsequent development of typhoid infection (diagnostic odds ratio (DOR) 0.57, 95%CI 0.12–2.71, p = 0.69) or development of S. Typhi bacteraemia (DOR 0.50, 95%CI 0.10–2.44, p = 0.45).
Of the 24 participants diagnosed with typhoid infection, 21/24 (87.5%) had a bacteraemia with or without reaching the clinical endpoint (Fig. 1, Supplementary Table 1). While culture-PCR and blood culture results concurred in participants with bacteraemia and fever, discrepancies arose in participants diagnosed by positive blood culture or temperature criteria alone. In three participants diagnosed by the clinical endpoint, 2/3 generated a positive culture-PCR result supporting the clinical diagnosis while all blood cultures remained negative throughout the challenge period (Fig. 1 and Supplementary Fig. 3). In addition, the participant treated early based on symptoms alone (i.e. no bacteraemia or fever) also had several positive culture-PCR assay results after the start of antimicrobial treatment.
In contrast, five participants had positive blood cultures on at least one occasion but remained PCR amplification negative throughout. In general, these five individuals had fewer positive blood cultures than those who generated positive blood cultures and were culture-PCR positive (mean, 2.00 vs. 2.73, respectively); this difference was non-significant (95%CI, −0.75 to 2.22, p = 0.31, T test).
Assuming that the predefined TD criteria were the best reference standard, culture-PCR demonstrated a sensitivity and specificity of 70 and 65%, respectively (Table 3). Despite forming part of the TD definition, the use of blood culture alone as a reference standard did not detect all cases of typhoid: routine blood culture was more sensitive and specific than culture-PCR; 87.5 and 100%, respectively. Interestingly, addition of the culture-PCR results to the study endpoint definitions suggested an overall attack rate after challenge of 73% rather than 59%. Discordant pairs analysis identified 12 mismatching culture-PCR and blood culture results, and confirmed that there was no significant difference in yield between culture-PCR and blood culture sensitivity if either was used alone to diagnose infection (p = 0.77, binomial test; Supplementary Table 2).
In participants who remained nTD throughout the 14-day observation period, 6/17 generated ≥1 positive culture-PCR result (Fig. 1). Further investigation of participants' clinical features demonstrated that several had features indicative of the development of typhoid infection in this controlled challenge scenario (Supplementary Table 3). These features included a single elevated temperature reading within 12 h of the positive culture-PCR result (Supplementary Fig. 4), maximal symptom reporting on the day of the positive culture-PCR result (Supplementary Table 3) and the additional participant who was treated based on symptoms without meeting the TD endpoint definition. The remaining 2/6 participants had only mild symptoms, reporting constipation and a cough on the day of the positive result.
Direct detection of pathogen nucleic acid is a widely-used method to increase sensitivity, specificity and time-to-result in modern diagnostic laboratories.30, 31, 32 We have previously described the first culture-PCR assay for detecting S. Typhi in the modern era20; here, we demonstrate the performance of this method, specifically designed to sensitively detect the S. Typhi fliC-d gene in the blood of participants undergoing typhoid challenge. While the direct comparison with blood culture suggested that the sensitivity of the assay was lower for participants reaching the typhoid diagnosis study endpoints, overall, the culture-PCR provided useful additional information compared with blood culture alone. This additional approach enabled the detection and confirmation of typhoid infection cases that would have been missed by blood culture. In using a human typhoid challenge model to perform the evaluation, we have provided unique insights into the natural history of typhoid infection. These include evidence for the frequency of asymptomatic infection after exposure, and the confirmation of bacterial DNA circulation in blood soon after exposure.
The application of PCR-based laboratory methods to confirm clinical diagnoses of typhoid fever are not commonly reported, despite the appeal of detecting non-cultivable bacteria. This is of special relevance in most endemic settings, where antimicrobial pre-treatment or immune interference are common and likely reduce culture sensitivity still further. In this study we demonstrate a PCR sensitivity of 70% using selective pre-incubation in ox-bile of a 5 mL blood sample, compared with the study defined endpoints. As reported previously, the median quantitative bacterial loads at diagnosis are 0.47 and 1.10 CFU/mL in participants ingesting the 103 or 104 CFU dose, respectively.21 With our estimation of a lower detection limit of 6 CFU/mL, it is not surprising that the assay may have failed to detect some cases. The extreme challenge posed by detecting such a small number of bacteria has been recently demonstrated in a field study evaluating a sensitive qPCR, capable of detecting ~1 CFU/mL, which, despite favourable performance in developmental stages demonstrated field performance of 40% sensitivity and 91% specificity.33
While the detection of bacterial DNA may be increased by pre-incubation of clinical material prior to performing DNA extraction,27, 34, 35 disadvantages to this method include loss of the ability to accurately quantify bacterial numbers in the blood directly, prolongation of assay time and the requirement for microbiological culture facilities. Nevertheless, selective culture to release viable bacteria from the blood intracellular compartment has been shown to produce an almost 2-fold rise in bacterial numbers.36 While broths containing 10% and more of ox-bile have been shown to be at best bacteriostatic for S. Typhi growth, our recent work identified that, at an optimal concentration of ~2.4% and with 5-h incubation, a significant increase in bacterial numbers may be achieved (Supplementary Table 4).18, 19 The addition of micrococcal nuclease during the extraction process to remove remaining human DNA further improved assay sensitivity.20
Our identification of participants with asymptomatic infection, i.e. participants who had evidence of DNA in the blood (positive culture-PCR result) or bacterial shedding in stool (positive stool culture) in the absence of fever or clinical signs of infection, may represent false positive assay results. While various S. Typhi targets have been used previously, Song and colleagues first described the use of PCR to detect flagellin sequences in 1993.12 Flagellin expression is monophasic in several Salmonella sp. including S. Typhi, and the phase-1 antigen ‘d’ is found in many species. While the end regions of fliC-d (previously H1-d) are identical between species, there are two hypervariable regions (IV and VI) unique to S. Typhi and similar to S. Muenchen.26 Selecting primers targeting this region should therefore result in good specificity with little overlap with environmental or other Salmonella species.
Identification of probable asymptomatic, subclinical typhoid patients has been previously noted in other susceptible patient groups including the historical typhoid challenge studies performed in Maryland.37 A study in Cambodia, for example, identified a subpopulation among children <16 years old presenting with fever who were culture-negative but positive using a real-time PCR assay.38 Of note, this subpopulation was younger, had a shorter duration of illness prior to presentation and presented with fewer features characteristic of typhoid infection. ‘Incomplete immunity’ and earlier presentation with illness are common to both patient/participant groups which may reflect higher bacterial loads.
The occurrence of a primary, subclinical, bacteraemia that results in the dissemination of bacteria to the lymphoreticular system has long been speculated.7, 16 While early studies demonstrated bacteraemia in patients and challenge study participants as early as 4 or 3 days, respectively,16, 37 these cases likely represented early true infection. Individuals were febrile and went on to develop overt clinical infection, probably as a result of high exposure dose, which has been shown to correlate to shorter incubation periods.21 Similar results were observed in studies performed in chimpanzees.39 Our culture-PCR results suggest that S. Typhi DNA is detectable in blood within 48 h after ingestion; data that are supported by corresponding increases in plasma cytokines and host gene expression activity.40 Factors affecting the outcome of these early invasion events, which probably occur more frequently than was recognised here as demonstrated by the ubiquitous cytokine signature found in challenged participants, are uncertain but probably include the host inflammatory responses and early immune responses.
There are known limitations to reporting of detecting S. Typhi DNA from clinical samples, which include the inappropriate validation of the methodology, using nested primers and use of archived samples rather than a real time comparison between culture and PCR technique.13 While some of these may be overcome by using real-time PCR, these techniques have reiterated the difficulty of amplifying very low DNA copy numbers which suggests its continued inferiority to standard bacterial culture.13 Overreliance on culture methods as the true reference standard is known to be problematic,33 however, and therefore corroborating clinical and stool culture data is also valuable.41
While PCR is a relatively commonly performed technique in most diagnostic laboratories, including those in less well-resourced settings, the pre-culture step, which is vital to increase assay sensitivity, does not yet render the procedure beyond cross-infection (or cross-contamination) risk. The highly selective nature of ox-bile, while suitable for S. Typhi and other bile resistant organisms, means that this assay is of questionable applicability to most settings where clinical material is scant and S. Typhi is not the predominant pathogen.6 Alternative lysing agents have been proposed, including saponin (used for bacterial blood quantification in this study) and digitonin, which may produce cell lysis without loss of bacterial viability.42, 43 In the specific context of vaccine field or probe studies, however, such a ‘mono-directional’ assay, possibly with the additional of targeted S. Paratyphi A primers,44 may offer additional support to validate efficacy at least in small scale studies.
An important limitation of our assay was the volume of blood required to perform the test. While the lower volumes may be used, the stochastic nature of sampling such low-density bacteraemic blood will necessarily result in a reduction in sensitivity. It is also important to note the difference between blood volumes used in our evaluation: blood culture was performed with 10 mL whereas the culture-PCR assay was performed with 5 mL. While detection of bacteraemia was key to the endpoint for the clinical study, ethical and physiological limitations to sampling meant that a matched volume could not be collected at every time point. This likely underestimates the performance of our culture-PCR assay.
In conclusion, a selective culture-PCR assay targeting the flagellin gene, while less sensitive than optimally performed blood culture for the detection of participants developing typhoid infection after challenge, provides useful additive diagnostic information regarding the outcome of typhoid challenge. Performing evaluation of newly available diagnostics in the context of a human challenge study highlights important features of the natural history of typhoid infection. These include the frequency of asymptomatic cases and new evidence for primary bacteraemia occurring soon after ingestion.
Funding for the challenge study was provided by a Wellcome Trust Strategic Translational Award (grant number 092661 to AJP; www.wellcome.ac.uk). Additional specific funding for this work was provided by Jesus College, Oxford (Graduate Scholarship to TCD).
TCD, CJ, CJB, CSW, AJP are supported by the NIHR Biomedical Research Centre (Oxford University Hospitals NHS Trust, Oxford; Clinical Research Fellowships to CSW and TCD); CJB is a Marie Curie Research Fellow supported by the European Union (FP7); AJP is a Jenner Investigator and James Martin Senior Fellow. SB is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (100087/Z/12/Z).
Conceived and designed the experiments: LZ, AJP, TCD. Performed the experiments: TCD, CJ, CJB, CSW. Analyzed the data: TCD, CJB. Contributed reagents/materials/analysis tools: TCD, LZ, CJ, CSW, SB. Wrote the paper: TCD, LZ, CJ, CJB, SB, AJP.
All authors report no conflict of interest.
We would like to express our thanks to the study participants for taking an active part in our research. We acknowledge the kind support of the microbiology, haematology and clinical chemistry laboratories at the Oxford Universities NHS Foundation Trust, and public health support from the Thames Valley Health Protection Unit. We are grateful to our colleague Professor Myron M Levine and the University of Maryland School of Medicine for providing the Quailes challenge strain, and to the Health Protection Agency (now Public Health England) Porton Down for challenge strain manufacture to GMP standard.
Appendix ASupplementary data related to this article can be found at http://dx.doi.org/10.1016/j.jinf.2017.01.006.
The following is the supplementary data related to this article: